Zaloguj Zarejestruj się zadarmo

Novabay Pharmaceuticals Inc organizacji Akcje w obiegu

Jaka jest wartość Akcje w obiegu organizacji Novabay Pharmaceuticals Inc?

Wartość Akcje w obiegu organizacji Novabay Pharmaceuticals Inc to 0.000 0.00%

Jaka jest definicja Akcje w obiegu?

Akcje w obiegu (Shares float) jest częścią akcji korporacji, które znajdują się w rękach inwestorów publicznych, a nie w postaci zablokowanych zapasów.

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Akcje w obiegu firm w Health Care sektor na NYSEMKT w porównaniu do Novabay Pharmaceuticals Inc

Czym się zajmuję organizacja Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Firmy z akcje w obiegu podobne do Novabay Pharmaceuticals Inc